Cipher Pharmaceuticals Inc.
CPHRF
$7.50
-$0.35-4.46%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 70.90% | 0.30% | 20.08% | 0.22% | 26.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.90% | 0.30% | 20.08% | 0.22% | 26.63% |
| Cost of Revenue | 83.09% | 4.24% | 7.98% | 2.03% | 25.12% |
| Gross Profit | 68.27% | -0.69% | 23.10% | -0.20% | 26.96% |
| SG&A Expenses | 172.49% | 4.36% | 24.51% | 25.88% | 22.11% |
| Depreciation & Amortization | 615.61% | -14.62% | -15.74% | -19.94% | -20.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.15% | -1.70% | 12.39% | 9.16% | 17.93% |
| Operating Income | -38.14% | 2.49% | 28.15% | -7.89% | 36.79% |
| Income Before Tax | -89.56% | -20.66% | 9.60% | 25.46% | 36.03% |
| Income Tax Expenses | 101.10% | -584.85% | -2,484.15% | 76.27% | -988.86% |
| Earnings from Continuing Operations | -95.97% | -2.47% | 87.47% | -61.10% | 164.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.97% | -2.47% | 87.47% | -61.10% | 164.92% |
| EBIT | -38.14% | 2.49% | 28.15% | -7.89% | 36.79% |
| EBITDA | 15.28% | 0.45% | 22.63% | -9.63% | 29.20% |
| EPS Basic | -95.97% | 2.48% | 96.18% | -59.72% | 163.32% |
| Normalized Basic EPS | -38.78% | -13.59% | 13.18% | 29.86% | 35.26% |
| EPS Diluted | -96.30% | 0.00% | 100.00% | -60.43% | 170.00% |
| Normalized Diluted EPS | -39.00% | -13.80% | 13.10% | 29.25% | 35.29% |
| Average Basic Shares Outstanding | -0.53% | -4.84% | -4.47% | -3.42% | 0.61% |
| Average Diluted Shares Outstanding | -0.02% | -4.49% | -4.53% | -2.96% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
